How to Check Sai Parenterals IPO Allotment Status

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.

The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets. The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology, across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.

Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.

The company owns and operates five manufacturing facilities in India, four in Hyderabad, Telangana (comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility) and one through its wholly owned subsidiary, Revat Laboratories, in Ongole, Andhra Pradesh. As of December 31, 2025, the company employed 298 full-time employees.

Sai Parenteral's IPO is a book build issue of ₹408.79 crore, comprising a fresh issue of 0.73 crore shares aggregating to ₹285.00 crore and an offer for sale of 0.32 crore shares aggregating to ₹123.79 crore. The IPO opened on March 24, 2026, and closed on March 27, 2026. The allotment is expected on Monday, March 30, 2026. The share price band was set at ₹372 to ₹392 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Sai Parenteral's IPO Allotment Status on Registrar Site

• Visit the BSE IPO Allotment Status Page Bigshare Services Pvt. Ltd.
• Select "Sai Parenteral's" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Sai Parenteral's IPO Allotment Status on BSE/NSE

• Navigate to the BSE IPO Allotment Status Page, NSE IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Sai Parenteral's" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Sai Parenteral's IPO Subscription Status

Sai Parenteral's IPO subscribed 1.08 times overall. Here is the category-wise breakdown as of 4:49:37 PM on March 27, 2026:

• QIB Category (Ex Anchor): 1.73 times
• Non-Institutional Investors (NII): 2.45 times
• Retail Investors: 0.12 times

Sai Parenteral's IPO Share Price and Investment Details

The minimum investment required was ₹14,896 for 1 lot (38 shares). The issue raised ₹122.64 crore from anchor investors. The anchor investor lock-in period ends on April 29, 2026 for 50% of shares (30 days) and June 28, 2026 for the remaining shares (90 days). Given the overall subscription of 1.08 times with moderate institutional interest at 1.73 times, healthy NII participation at 2.45 times, and weak retail subscription at 0.12 times, the share price listing expectations remain cautious.

Utilisation of IPO Proceeds

The proceeds will be utilised for capacity expansion and upgradation of manufacturing facilities (₹110.80 crore), establishment of a new R&D Centre (₹18.02 crore), repayment/prepayment of certain outstanding borrowings (₹14.30 crore), working capital requirements (₹33.00 crore), investment in wholly owned subsidiary Sai Parenterals Pte Limited (Singapore) in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) (₹35.64 crore), and general corporate purposes.

Business Overview

Sai Parenteral's Limited is a well-diversified pharmaceutical formulation development and manufacturing company. It has branded generic formulations as well as CDMO products for domestic and international markets. The company has a backup of 500+ dossiers which puts it on a fast forward mode. Post completion of backward integrations and de-bottlenecking of plant capacity at its Australia facility, it is set for speedy growth in top and bottom lines.

The company demonstrated financial performance with total income of ₹163.74 crore for FY2025 and a net worth of ₹209.37 crore as of September 30, 2025. The company benefits from being a diversified generic formulations player with an established track record, strategically located and accredited manufacturing facilities, a strong focus on the CDMO business, a well-established distribution network in India and overseas, a track record of value-accretive acquisitions, and experienced promoters and senior management with extensive domain knowledge. However, investors should note the post-issue P/E ratio of 72.19 and Price to Book Value of 10.89.